These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 22894757)

  • 1. Discovery of highly selective and orally active lysophosphatidic acid receptor-1 antagonists with potent activity on human lung fibroblasts.
    Qian Y; Hamilton M; Sidduri A; Gabriel S; Ren Y; Peng R; Kondru R; Narayanan A; Truitt T; Hamid R; Chen Y; Zhang L; Fretland AJ; Sanchez RA; Chang KC; Lucas M; Schoenfeld RC; Laine D; Fuentes ME; Stevenson CS; Budd DC
    J Med Chem; 2012 Sep; 55(17):7920-39. PubMed ID: 22894757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel non-carboxylic acid 5-amino-4-cyanopyrazole derivatives as potent and highly selective LPA1R antagonists.
    Sidduri A; Budd DC; Fuentes ME; Lambros T; Ren Y; Roongta V; Schoenfeld RC; Gillespie P; Stevenson CS; Truitt T; Qian Y
    Bioorg Med Chem Lett; 2014 Sep; 24(18):4450-4454. PubMed ID: 25155385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initial structure-activity relationships of lysophosphatidic acid receptor antagonists: discovery of a high-affinity LPA1/LPA3 receptor antagonist.
    Heasley BH; Jarosz R; Lynch KR; Macdonald TL
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2735-40. PubMed ID: 15125924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist.
    Swaney JS; Chapman C; Correa LD; Stebbins KJ; Broadhead AR; Bain G; Santini AM; Darlington J; King CD; Baccei CS; Lee C; Parr TA; Roppe JR; Seiders TJ; Ziff J; Prasit P; Hutchinson JH; Evans JF; Lorrain DS
    J Pharmacol Exp Ther; 2011 Mar; 336(3):693-700. PubMed ID: 21159750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of lysophosphatidic acid receptors LPAR1/3 ameliorates lung fibrosis induced by irradiation.
    Gan L; Xue JX; Li X; Liu DS; Ge Y; Ni PY; Deng L; Lu Y; Jiang W
    Biochem Biophys Res Commun; 2011 May; 409(1):7-13. PubMed ID: 21545790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing the differential effects of LPA on the barrier function of human pulmonary endothelial cells.
    Ren Y; Guo L; Tang X; Apparsundaram S; Kitson C; Deguzman J; Fuentes ME; Coyle L; Majmudar R; Allard J; Truitt T; Hamid R; Chen Y; Qian Y; Budd DC
    Microvasc Res; 2013 Jan; 85():59-67. PubMed ID: 23084965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translational engagement of lysophosphatidic acid receptor 1 in skin fibrosis: from dermal fibroblasts of patients with scleroderma to tight skin 1 mouse.
    Ledein L; Léger B; Dees C; Beyer C; Distler A; Vettori S; Boukaiba R; Bidouard JP; Schaefer M; Pernerstorfer J; Ruetten H; Jagerschmidt A; Janiak P; Distler JHW; Distler O; Illiano S
    Br J Pharmacol; 2020 Sep; 177(18):4296-4309. PubMed ID: 32627178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphonothioate and fluoromethylene phosphonate analogues of cyclic phosphatidic acid: Novel antagonists of lysophosphatidic acid receptors.
    Xu Y; Jiang G; Tsukahara R; Fujiwara Y; Tigyi G; Prestwich GD
    J Med Chem; 2006 Aug; 49(17):5309-15. PubMed ID: 16913720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model.
    Swaney JS; Chapman C; Correa LD; Stebbins KJ; Bundey RA; Prodanovich PC; Fagan P; Baccei CS; Santini AM; Hutchinson JH; Seiders TJ; Parr TA; Prasit P; Evans JF; Lorrain DS
    Br J Pharmacol; 2010 Aug; 160(7):1699-713. PubMed ID: 20649573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anatomical location of LPA1 activation and LPA phospholipid precursors in rodent and human brain.
    González de San Román E; Manuel I; Giralt MT; Chun J; Estivill-Torrús G; Rodríguez de Fonseca F; Santín LJ; Ferrer I; Rodríguez-Puertas R
    J Neurochem; 2015 Aug; 134(3):471-85. PubMed ID: 25857358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel series of 2-pyridyl-containing compounds as lysophosphatidic acid receptor antagonists: development of a nonhydrolyzable LPA3 receptor-selective antagonist.
    Heasley BH; Jarosz R; Carter KM; Van SJ; Lynch KR; Macdonald TL
    Bioorg Med Chem Lett; 2004 Aug; 14(15):4069-74. PubMed ID: 15225728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidepressants induce profibrotic responses via the lysophosphatidic acid receptor LPA
    Olianas MC; Dedoni S; Onali P
    Eur J Pharmacol; 2020 Apr; 873():172963. PubMed ID: 32007501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lysophosphatidic acid and its receptor LPA
    Srikanth M; Chew WS; Hind T; Lim SM; Hay NWJ; Lee JHM; Rivera R; Chun J; Ong WY; Herr DR
    Eur J Pharmacol; 2018 Dec; 841():49-56. PubMed ID: 30321532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subtype-selective antagonists of lysophosphatidic Acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques.
    Rother E; Brandl R; Baker DL; Goyal P; Gebhard H; Tigyi G; Siess W
    Circulation; 2003 Aug; 108(6):741-7. PubMed ID: 12885756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Agonist-induced endocytosis of lysophosphatidic acid-coupled LPA1/EDG-2 receptors via a dynamin2- and Rab5-dependent pathway.
    Murph MM; Scaccia LA; Volpicelli LA; Radhakrishna H
    J Cell Sci; 2003 May; 116(Pt 10):1969-80. PubMed ID: 12668728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA
    Cheng PTW; Kaltenbach RF; Zhang H; Shi J; Tao S; Li J; Kennedy LJ; Walker SJ; Shi Y; Wang Y; Dhanusu S; Reddigunta R; Kumaravel S; Jusuf S; Smith D; Krishnananthan S; Li J; Wang T; Heiry R; Sum CS; Kalinowski SS; Hung CP; Chu CH; Azzara AV; Ziegler M; Burns L; Zinker BA; Boehm S; Taylor J; Sapuppo J; Mosure K; Everlof G; Guarino V; Zhang L; Yang Y; Ruan Q; Xu C; Apedo A; Traeger SC; Cvijic ME; Lentz KA; Tirucherai G; Sivaraman L; Robl J; Ellsworth BA; Rosen G; Gordon DA; Soars MG; Gill M; Murphy BJ
    J Med Chem; 2021 Nov; 64(21):15549-15581. PubMed ID: 34709814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors.
    Ohta H; Sato K; Murata N; Damirin A; Malchinkhuu E; Kon J; Kimura T; Tobo M; Yamazaki Y; Watanabe T; Yagi M; Sato M; Suzuki R; Murooka H; Sakai T; Nishitoba T; Im DS; Nochi H; Tamoto K; Tomura H; Okajima F
    Mol Pharmacol; 2003 Oct; 64(4):994-1005. PubMed ID: 14500756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abrogation of lysophosphatidic acid receptor 1 ameliorates murine vasculitis.
    Miyabe C; Miyabe Y; Nagai J; Miura NN; Ohno N; Chun J; Tsuboi R; Ueda H; Miyasaka M; Miyasaka N; Nanki T
    Arthritis Res Ther; 2019 Aug; 21(1):191. PubMed ID: 31429784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lysophosphatidic Acid Signaling through the Lysophosphatidic Acid-1 Receptor Is Required for Alveolarization.
    Funke M; Knudsen L; Lagares D; Ebener S; Probst CK; Fontaine BA; Franklin A; Kellner M; Kühnel M; Matthieu S; Grothausmann R; Chun J; Roberts JD; Ochs M; Tager AM
    Am J Respir Cell Mol Biol; 2016 Jul; 55(1):105-16. PubMed ID: 27082727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of aberrant DNA methylation on reduced expression of lysophosphatidic acid receptor-1 gene in rat tumor cell lines.
    Tsujiuchi T; Shimizu K; Onishi M; Sugata E; Fujii H; Mori T; Honoki K; Fukushima N
    Biochem Biophys Res Commun; 2006 Oct; 349(3):1151-5. PubMed ID: 16970915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.